While there is no guarantee of either, you are trying to choose between therapies based on averages. The articles linked an excerpted below speak to one of the most frequently asked questions I hear from newly diagnosed myeloma patients. “Should I have my autologous stem cell transplant now or should I wait?”
I believe that if newly-diagnosed multiple myeloma patients are not going to sacrifice overall survival by waiting then they should wait.
Multiple Myeloma at a glance- click the image below:
Many patients tell me that their oncologists are pushing for an ASCT now but they want to wait. The articles below answer an important question. There is NO difference based on your overall survival aka length of life.
And make no mistake. An autologous stem cell transplant is high-dose chemotherapy and is very toxic. When I had my ASCT at 36, the procedure left me with a host of short, long-term and late stage side effects. Novel therapies such as Revlimid, Velcade, etc. have questioned the benefit of autologous stem cell transplantation for multiple myeloma patients.
Progression-Free Survival- The time for your multiple myeloma to progress from the date of your ASCT.
Overall Survival- The is how long MM patients live. Length of life. PFS measures time to when the cancer begins growing again after therapy.
In addition to the long and growing list of FDA-approved chemotherapy regimens that are cytotoxic to multiple myeloma, there is also a long and growing list of evidence-based, non-toxic therapies that are cytotoxic to multiple myeloma. I have lived in complete remission from my MM since ’99 by living an evidence-based, anti-MM lifestyle through nutrition, supplementation, bone health, etc.
I am both a long-term MM survivor and MM Cancer Coach. Click the link on the right of the page now to watch a free webinar about the Multiple Myeloma Cancer Coaching Program that I designed and created based on my 22 plus years living with MM.
Have you been diagnosed with multiple myeloma? What stage? Are you experiencing any symptoms such as bone pain, anemia or kidney damage?
Scroll down the page to post a question or comment. Thanks and hang in there.
“Results from a retrospective study show that delaying stem cell transplantation following initial therapy may result in shorter progression-free survival following transplantation compared to transplantation soon after diagnosis.
However, the results also show that the timing of transplantation does not significantly impact overall survival…
Over the past 15 years, however, studies have shown that novel anti-myeloma agents – such as thalidomide(Thalomid), Revlimid (lenalidomide), and Velcade (bortezomib) – extend the progression-free and overall survival of myeloma patients. Due to the efficacy and high tolerability of the novel agents, many myeloma patients in recent years have been choosing to delay or forego stem cell transplantation…”
” In summary, early or late ASCT is a viable option for patients with MM receiving induction treatment with novel targeted therapies.”